Work

Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer

Year: 2004

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2004.22.14_suppl.2000

Authors: A. B. Sandler, G. R. Blumenschein, T. Henderson, J. Lee, M. Truong, E. Kim, B. Mass, B. Garcia, D. H. Johnson, R. S. Herbst

Institutions: The University of Texas MD Anderson Cancer Center, Genentech, Vanderbilt-Ingram Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2604162954

Cites:

Cited by: 37

Related to: 10